Jefferies lowers Colgate-Palmolive stock price target on cost concerns

Jefferies cut Colgate-Palmolive’s price target to $88 from $91 and kept a Hold rating, citing rising input costs, demand sensitivity, and uncertainty into the rest of 2026. The firm expects Q1 delivery to remain on track but sees the company likely guiding toward the low end of its 2026 range, while trimming its EPS growth estimate to 3% versus 4% Street consensus. Separate updates included leadership succession in the legal department and other analyst actions, but the overall tone remains cautious.

Analysis

The market is starting to price a more persistent margin squeeze in branded staples, but the bigger issue is not this quarter’s EPS—it’s the probability that pricing power decays just as input inflation re-accelerates. That combination usually compresses multiple first, earnings second: investors punish the perception that a defensible category is turning into a low-growth pass-through business. In that regime, name-brand defensives with weaker innovation cadence tend to underperform private-label exposure and faster-moving food/household peers over the next 3-6 months.

The downgrade cascade matters because it narrows the bull case from “safe compounder” to “bond proxy with modest growth,” which is a bad place to be when rates are still sticky and consumer trade-down is increasing. If management leans to the low end of guidance, the market will likely extrapolate that to 2027, not just 2026, because the key variable is the duration of margin pressure. The second-order effect is channel behavior: retailers are likely to push harder on promotions and shelf mix, which can protect volumes but further dilute realized price and delay any gross margin recovery.

The contrarian angle is that this may be a valuation reset more than a fundamental break. If commodity inputs stabilize for even one quarter, CL can look optically cheap quickly because the business has a lot of mechanical earnings leverage to moderation in packaging, freight, and raw materials. That means the downside is probably more time decay than permanent impairment, but the upside is capped until there is evidence of normalized input trends and less promotional intensity.

Best risk/reward is to fade the near-term defensiveness rather than outright bet on a collapse. The stock is vulnerable into commentary that validates lower-end guidance, but a clean miss would be needed to justify a larger structural short; absent that, this is a relative-value call, not a fundamental melt-down story.

Key Decisions for Investors

• Short CL into earnings/guide commentary over the next 2-6 weeks; target 5-8% downside if management confirms lower-end guidance and softer margin tone. Cover on any explicit evidence that input costs are rolling over.
• Pair trade: long DB / short CL for 1-3 months. DB has positive revision momentum and operating leverage, while CL is at risk of estimate compression; expect 300-500 bps relative outperformance if the macro tape stays mixed.
• Buy CL put spreads 1-2 strikes below spot with 60-90 day expiry if implied vol is not elevated. Risk/reward favors defined-risk downside exposure because the catalyst is commentary-driven and the move is likely gradual rather than gap-only.
• For long-only portfolios, underweight CL versus higher-quality consumer staples with better pricing or mix levers for the next quarter. CL is still defensible, but the expected return profile is poor relative to names with more visible catalyst support.
• Reassess any short after results if gross margin assumptions are unchanged and guidance is reiterated without a low-end bias; that would remove the near-term catalyst and likely force shorts to cover.